← Back to Search

Radiation Therapy

Group 2: Peripherally Located Chest Wall Adjacent Tumors for Non-Small Cell Lung Cancer

N/A
Waitlist Available
Led By Matthew Harkenrider, MD
Research Sponsored by Loyola University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 104 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the hypothesis that SBRT results in a higher rate of tumor control and longer overall survival compared to EBRT in medically inoperable early-stage NSCLC patients.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~104 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 104 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Toxicity Evaluation
Secondary study objectives
Disease Specific Outcomes

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Group 3: Centrally Located TumorsExperimental Treatment1 Intervention
Centrally Located Tumors - SBRT
Group II: Group 2: Peripherally Located Chest Wall Adjacent TumorsExperimental Treatment1 Intervention
Peripherally Located Chest Wall Adjacent Tumors - SBRT
Group III: Group 1: Peripherally Located TumorsExperimental Treatment1 Intervention
Peripherally Located Tumors - SBRT

Find a Location

Who is running the clinical trial?

Loyola UniversityLead Sponsor
160 Previous Clinical Trials
31,378 Total Patients Enrolled
Matthew Harkenrider, MDPrincipal InvestigatorEdward Hines Jr. VA Hospital
1 Previous Clinical Trials
24 Total Patients Enrolled
~4 spots leftby Nov 2025